NMS·Healthcare·$383M·#66 / 520 in Healthcare
PBYI Puma Biotechnology Inc
69SOLID
CATEGORY BREAKDOWN
GROWTH0
QUALITY77
STABILITY94
VALUATION97
GOVERNANCE79
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-0.9%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
74.5%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
21.9%
82
< 25% strong
Price / Sales
Market cap relative to trailing revenue
1.7x
97
< 3x strong
Rule of 40
Growth rate plus operating margin
15
43
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
15.4%
76
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+2.6%
85
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE PBYI WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when PBYI's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.